Francis Lo Sells 44,838 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 44,838 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total value of $1,012,890.42. Following the sale, the insider owned 230,713 shares of the company’s stock, valued at approximately $5,211,806.67. This represents a 16.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, July 1st, Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.45, for a total value of $1,145,039.80.
• On Thursday, June 4th, Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.49, for a total value of $695,070.09.
• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total transaction of $340,039.48.

Adaptive Biotechnologies Trading Down 3.2%

ADPT opened at $20.82 on Wednesday. The company has a market cap of $3.33 billion, a P/E ratio of -63.09 and a beta of 2.07. The company’s 50 day moving average is $16.38 and its 200-day moving average is $15.94. Adaptive Biotechnologies Corporation has a 1-year low of $9.96 and a 1-year high of $22.80.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same period in the prior year, the company earned ($0.20) EPS. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently made changes to their positions in ADPT. Ameriprise Financial Inc. increased its position in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $65,942,000. Geode Capital Management LLC boosted its stake in shares of Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after purchasing an additional 110,825 shares during the last quarter. Finally, State Street Corp increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after buying an additional 102,362 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ADPT has been the topic of several recent research reports. TD Cowen raised their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Guggenheim increased their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Morgan Stanley reduced their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $20.50.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.